Copyright
©The Author(s) 2022.
World J Cardiol. Jul 26, 2022; 14(7): 382-391
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.382
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.382
Figure 1 Coronavirus disease 2019 vaccine-mediated myocarditis and pericarditis cases reported to Vaccine Adverse Event Reporting System.
A: Age. A total of 4317 events of myocarditis and pericarditis after receiving coronavirus disease 2019 (COVID-19) vaccine were reported to Vaccine Adverse Event Reporting System (VAERS) as of December 31, 2021. Age group 18-29 had the highest number of cases reported for myocarditis (763 cases) as well as pericarditis (404 cases). Adapted from centers for disease control and prevention (CDC) WONDER and VAERS which is updated weekly for continuous updates including revisions and new reports for preceding time periods[9]; B: Vaccine manufacturer. A total of 2512 cases of myocarditis and 1805 cases pericarditis after receiving COVID-19 vaccine were reported to VAERS as of December 31, 2021. Pfizer-BioNTech™ had the highest number of cases reported for myocarditis (1615 cases) as well as pericarditis (1063 cases). Adapted from CDC WONDER and VAERS which is updated weekly for continuous updates including revisions and new reports for preceding time periods[11]. COVID-19: Coronavirus disease 2019.
- Citation: Morgan MC, Atri L, Harrell S, Al-Jaroudi W, Berman A. COVID-19 vaccine-associated myocarditis. World J Cardiol 2022; 14(7): 382-391
- URL: https://www.wjgnet.com/1949-8462/full/v14/i7/382.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i7.382